---
title: Mandatory notification of trade
description: Mandatory notification of trade Moss, 8 May 2025
---

Moss, 8 May 2025

Gentian Diagnostics ASA ("Gentian") has today been notified that the following transaction has been completed:

Norda ASA has purchased 101,848 shares in Gentian at NOK 51.50 per share. Following the transaction Norda ASA owns 716,099 shares in Gentian. Norda ASA owns about 4.64% of the total outstanding shares following the transaction. Norda ASA will together with the Group of companies Kvantia AS, Obligasjon 2 AS, Caaby AS, RWD AS, Insr ASA and Victoria India Fund AS following the share transaction hold in total 3,524,218 shares in Gentian, corresponding to approx. 22.85% of the total outstanding shares.

Christian Åbyholm is Chairman of the Board of Norda ASA and is a Member of the Board of Directors and primary insider in Gentian.

PCA notification pursuant to the EU Market Abuse Regulation Article 19 is attached.

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act, EU Market Abuse Regulation Article 19 and Euronext Oslo Rule Book II.

 

For further information, please contact:

Njaal Kind, Group CFO  
[njaal.kind@gentian.no](mailto:njaal.kind@gentian.no)

+47 91 90 65 25

### You may also read

[Jul 02, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1746691953935#)

##### [Gentian Diagnostics: Invitation to presentation of second quarter results](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-invitation-to-presentation-of-second-quarter-results-1)

Gentian Diagnostics ASA will present its second quarter 2026 results on 9 July 2026 at 09.00 CEST. The..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-invitation-to-presentation-of-second-quarter-results-1)

[Jun 24, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1746691953935#)

##### [ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT](https://www.gentian.com/investor-relations-stock-information/investors-news/essange-reagents-and-gentian-diagnostics-announce-collaboration-agreement)

Amsterdam / Moss, 24 June 2026 ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/essange-reagents-and-gentian-diagnostics-announce-collaboration-agreement)

[May 29, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1746691953935#)

##### [Mandatory notification of trade](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1780055230560)

Moss, 29 May 2026 Gentian Diagnostics ASA ("Gentian") has today been notified that the following transaction..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1780055230560)